Imiquimod CAS 99011-02-6

Product Description:

Product Name: Imiquimod CAS NO: 99011-02-6

Synonyms:

1-(2-Methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, R-837, S-26308, Aldara;

1--methylpropyl)-1H-imidazo(4,5-quinolin-4-amine);

4-amino- 1-isobutyl-1h-imidazo[4,5-c]quinoline;

Chemical & Physical Properties:

Appearance: White to off white crystalline powder

Assay :≥99.00%

Density: 1.28 g/cm3

Boiling Point: 456.7℃ at 760 mmHg

Melting Point: 292-294℃

Flash Point: 230℃

Stability: Incompatible with strong oxidizing agents.

Storage Condition: Store in original container in a cool dark place.

Water Solubility: Soluble in dimethyl sulfoxide and dimethyl formamide. Slightly soluble in water. Insoluble in ethanol.

Safety Information:

Safety Statements: S26-S27-S36/37/39-S45

HS Code: 2933990090

RIDADR: UN 2811 6.1/PG 3

Risk Statements: R25; R36/37/38

Hazard Codes: T; Xi

Hazard Class: 6.1

Packing Group: III

An immune response modifier. It stimulates the production of interferon-a. It can be used for the treatment of adult external genital and perianal genital warts at 3 times per week. Just before sleep, first apply the product evenly in a thin layer on the surface of the wart and gently massage until the product is completely absorbed. The position of the medication should not be packeted and should be maintained for 6 to 10 hours, and then wash with a neutral soap and clean water for clearing the drugs in the administration site. Wash your hands before and after treatment. 250 mg of cream can be applied to 20cm2 of wart. Avoid excessive application of the drug. Patients should continue the treatment until the wart is completely cleared. Wart can be cleared within 2-4 week at the fastest speed and can be generally cleared within 8 to 12 weeks. The medication should be not more than 16 weeks. After the treatment, patients with mild erythema locally who does not have to be discontinued for drug; if the patients feel general malaise or get local skin reactions (edema, erosion, pain, etc.), the drug should be discontinued. Only when the reaction is alleviated can they continue the medication.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.